🇺🇸 FDA
Pipeline program

Pimavanserin Capsules 10 mg, Pimavanserin 34 mg Capsule, Pimavanserin 20 mg Capsule

ACP-103-070

Phase 2 small_molecule active

Quick answer

Pimavanserin Capsules 10 mg, Pimavanserin 34 mg Capsule, Pimavanserin 20 mg Capsule for Irritability associated with autistic disorder in children and adolescents with ASD is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Irritability associated with autistic disorder in children and adolescents with ASD
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials